-
Here's Why Regulus Therapeutics Gained 20%
Wednesday, February 17, 2016 - 1:09pm | 252Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were trading higher by nearly 20 percent late Wednesday morning after the company announced interim results from an ongoing Phase 2 study. Regulus Therapeutics' Phase 2 study of RG-101 for the treatment of Hepatitis C Virus infection (HCV) was...